Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Update

by · The Markets Daily

Curanex Pharmaceuticals Inc (NASDAQ:CURX – Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 2,823 shares, a growth of 528.7% from the August 31st total of 449 shares. Based on an average daily trading volume, of 31,637 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company’s shares are short sold.

Curanex Pharmaceuticals Stock Performance

NASDAQ:CURX traded up $0.28 during mid-day trading on Friday, hitting $4.72. The company had a trading volume of 71,262 shares, compared to its average volume of 21,209. Curanex Pharmaceuticals has a fifty-two week low of $3.58 and a fifty-two week high of $21.00. The firm has a market cap of $7.42 million and a P/E ratio of -0.61. The business’s fifty day moving average is $4.37 and its two-hundred day moving average is $6.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Curanex Pharmaceuticals currently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on Curanex Pharmaceuticals

Curanex Pharmaceuticals Company Profile

(Get Free Report)

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.

Recommended Stories